NZ555120A - Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition - Google Patents

Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition

Info

Publication number
NZ555120A
NZ555120A NZ555120A NZ55512005A NZ555120A NZ 555120 A NZ555120 A NZ 555120A NZ 555120 A NZ555120 A NZ 555120A NZ 55512005 A NZ55512005 A NZ 55512005A NZ 555120 A NZ555120 A NZ 555120A
Authority
NZ
New Zealand
Prior art keywords
compound
range
employed
amount
potassium salt
Prior art date
Application number
NZ555120A
Other languages
English (en)
Inventor
Nazaneen Pourkavoos
James R Ney
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ555120(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NZ555120A publication Critical patent/NZ555120A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ555120A 2004-12-03 2005-12-02 Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition NZ555120A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63294404P 2004-12-03 2004-12-03
PCT/US2005/043727 WO2006060711A2 (en) 2004-12-03 2005-12-02 Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition

Publications (1)

Publication Number Publication Date
NZ555120A true NZ555120A (en) 2009-11-27

Family

ID=36118082

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ555120A NZ555120A (en) 2004-12-03 2005-12-02 Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition

Country Status (16)

Country Link
US (1) US8852632B2 (cg-RX-API-DMAC7.html)
EP (2) EP2586444B1 (cg-RX-API-DMAC7.html)
JP (1) JP5228488B2 (cg-RX-API-DMAC7.html)
KR (1) KR101351059B1 (cg-RX-API-DMAC7.html)
CN (1) CN101068550B (cg-RX-API-DMAC7.html)
AU (1) AU2005311652B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518781A2 (cg-RX-API-DMAC7.html)
CA (1) CA2588445C (cg-RX-API-DMAC7.html)
ES (1) ES2755273T3 (cg-RX-API-DMAC7.html)
IL (1) IL183615A (cg-RX-API-DMAC7.html)
MX (1) MX2007006635A (cg-RX-API-DMAC7.html)
NO (1) NO20073405L (cg-RX-API-DMAC7.html)
NZ (1) NZ555120A (cg-RX-API-DMAC7.html)
RU (1) RU2382648C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006060711A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200703866B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101068533B (zh) * 2004-12-03 2011-04-27 默沙东公司 含有抗成核剂的药物组合物
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CA2588466A1 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
WO2009009531A2 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
JP6122639B2 (ja) * 2009-10-26 2017-04-26 メルク・シャープ・エンド・ドーム・コーポレイション インテグラーゼ阻害剤を含有する固形医薬組成物
US8987272B2 (en) * 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
ES2450944T3 (es) * 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
WO2014030172A2 (en) * 2012-08-23 2014-02-27 Hetero Research Foundation Pharmaceutical formulations of rufinamide
US9763934B2 (en) * 2014-03-05 2017-09-19 Professional Compounding Centers Of America Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
US20210290548A1 (en) * 2018-06-06 2021-09-23 Merck Sharp & Dohme Corp. Formulations of raltegravir

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56992C2 (uk) * 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
CN100400042C (zh) * 1999-12-03 2008-07-09 聚合化学股份公司 制备生物利用度改善的麦角生物碱持续释放药物组合物的方法及其组合物
PL366998A1 (en) * 2001-05-03 2005-02-07 F.Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
CN1700918B (zh) * 2001-10-26 2011-06-08 P·安杰莱蒂分子生物学研究所 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
CA2463975A1 (en) * 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
AU2003220186A1 (en) * 2002-04-10 2003-10-27 Merck And Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
BR0317749A (pt) * 2002-12-27 2005-11-22 Angeletti P Ist Richerche Bio Composto, composição farmacêutica, e, uso de um composto
DE602004031767D1 (de) 2003-12-31 2011-04-21 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CA2588466A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
CN101068533B (zh) * 2004-12-03 2011-04-27 默沙东公司 含有抗成核剂的药物组合物

Also Published As

Publication number Publication date
KR20070085695A (ko) 2007-08-27
JP2008521932A (ja) 2008-06-26
MX2007006635A (es) 2007-06-19
WO2006060711A2 (en) 2006-06-08
ES2755273T3 (es) 2020-04-22
IL183615A (en) 2013-01-31
EP1904067A2 (en) 2008-04-02
CN101068550A (zh) 2007-11-07
KR101351059B1 (ko) 2014-02-17
EP1904067B1 (en) 2013-11-20
JP5228488B2 (ja) 2013-07-03
CA2588445C (en) 2013-06-25
IL183615A0 (en) 2007-10-31
US20070292504A1 (en) 2007-12-20
WO2006060711A3 (en) 2006-09-08
CA2588445A1 (en) 2006-06-08
BRPI0518781A2 (pt) 2008-12-09
EP2586444A1 (en) 2013-05-01
AU2005311652A1 (en) 2006-06-08
RU2007125122A (ru) 2009-01-10
ZA200703866B (en) 2008-03-26
EP2586444B1 (en) 2019-09-25
US8852632B2 (en) 2014-10-07
EP1904067B2 (en) 2017-10-11
AU2005311652B2 (en) 2010-12-02
CN101068550B (zh) 2011-03-30
RU2382648C2 (ru) 2010-02-27
NO20073405L (no) 2007-07-02

Similar Documents

Publication Publication Date Title
IL183615A (en) Pharmaceutical formulation of HIV carboxamide amide-containing inhibitors containing the controlled-release composition
US10772888B2 (en) Solid pharmaceutical compositions containing an integrase inhibitor
JP2012184250A (ja) 抗核形成剤を含有する医薬組成物
CA2800446A1 (en) Solid ivabradine-containing composition
US20090136570A1 (en) Taste-Masked Tablets and Granules
WO2020109319A1 (en) Pharmaceutical composition comprising ramipril and indapamide
JP6123795B2 (ja) 放出制御医薬組成物
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: SCHERING CORPORATION, US

Free format text: OLD OWNER(S): MERCK SHARP AND DOHME CORP.

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2016 BY THOMSON REUTERS

Effective date: 20151118

LAPS Patent lapsed